Key result
This review discusses epigenetic mechanisms in atrial fibrillation and the potential of sodium-glucose cotransporter 2 inhibitors to modify epigenetic signatures and disease progression.
Why the study?
Emerging evidence on the epigenetic effects of SGLT2 inhibitors provided a rationale to investigate their potential role in the onset and progression of atrial fibrillation.
Design
Review
Authors
Loading...
New insights into atrial remodeling extend AF mechanistic understanding; hypothesis-generating with no immediate clinical implications.
This review highlights the emerging role of epigenetic mechanisms in atrial fibrillation and proposes a potential therapeutic role for SGLT2 inhibitors in modifying these pathways.
Donniacuo et al. (2022) conducted a review in Atrial fibrillation. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) was evaluated. This review discusses epigenetic mechanisms in atrial fibrillation and the potential of sodium-glucose cotransporter 2 inhibitors to modify epigenetic signatures and disease progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: